Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chirikov

Showing results (51-60 of 106) with videos related to

Pageof 11
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 4, 2019
Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United StatesViktor Chirikov, Ingrid Ma, Namita Joshi, et al.
Medical Care|November 15, 2017
Tree-based Claims Algorithm for Measuring Pretreatment Quality of Care in Medicare Disabled Hepatitis C PatientsViktor V Chirikov, Fadia T Shaya, Ebere Onukwugha, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 9, 2025
Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up resultsDaniel Lin, Wenying Quan, Marne Garretson, et al.
Dermatology and Therapy|June 22, 2024
Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc AnalysisApril W Armstrong, Sang Hee Park, Vardhaman Patel, et al.
Dermatology and Therapy|October 18, 2023
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque PsoriasisApril W Armstrong, Sang Hee Park, Vardhaman Patel, et al.
Clinical Drug Investigation|January 27, 2019
Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in ChinaYan Xu, Ningying Mao, Viktor Chirikov, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 4, 2013
Social networks help control hypertensionFadia T Shaya, Viktor V Chirikov, C Daniel Mullins, et al.
Current Medical Research and Opinion|January 8, 2026
Comorbidity and comedication burden in people living with HIV in the United States: updated findings from a contemporary cohort (2020-2024)Sean P Fleming, Shweta Kamat, Girish Prajapati, et al.
Journal of Epidemiology and Community Health|December 4, 2013
Effect of social networks intervention in type 2 diabetes: a partial randomised studyFadia T Shaya, Viktor V Chirikov, Deleonardo Howard, et al.
Clinical and Translational Gastroenterology|December 31, 2025
Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney InjuryStevan A Gonzalez, Andrew S Allegretti, Viktor V Chirikov, et al.
Pageof 11

Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 4, 2019
Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United StatesViktor Chirikov, Ingrid Ma, Namita Joshi, et al.
Medical Care|November 15, 2017
Tree-based Claims Algorithm for Measuring Pretreatment Quality of Care in Medicare Disabled Hepatitis C PatientsViktor V Chirikov, Fadia T Shaya, Ebere Onukwugha, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 9, 2025
Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up resultsDaniel Lin, Wenying Quan, Marne Garretson, et al.
Dermatology and Therapy|June 22, 2024
Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc AnalysisApril W Armstrong, Sang Hee Park, Vardhaman Patel, et al.
Dermatology and Therapy|October 18, 2023
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque PsoriasisApril W Armstrong, Sang Hee Park, Vardhaman Patel, et al.
Clinical Drug Investigation|January 27, 2019
Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in ChinaYan Xu, Ningying Mao, Viktor Chirikov, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 4, 2013
Social networks help control hypertensionFadia T Shaya, Viktor V Chirikov, C Daniel Mullins, et al.
Current Medical Research and Opinion|January 8, 2026
Comorbidity and comedication burden in people living with HIV in the United States: updated findings from a contemporary cohort (2020-2024)Sean P Fleming, Shweta Kamat, Girish Prajapati, et al.
Journal of Epidemiology and Community Health|December 4, 2013
Effect of social networks intervention in type 2 diabetes: a partial randomised studyFadia T Shaya, Viktor V Chirikov, Deleonardo Howard, et al.
Clinical and Translational Gastroenterology|December 31, 2025
Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney InjuryStevan A Gonzalez, Andrew S Allegretti, Viktor V Chirikov, et al.
Pageof 11